Sinovac Biotech Ltd. a provider of biopharmaceutical products in China, announced that Sinovac Beijing, the main operating subsidiary company of Sinovac, obtained the Certificate of Good Manufacturing Practices for Pharmaceutical Products (GMP Certificate) from the China State and Food Administration (CFDA) for its proprietary vaccines, its Haidian district bulk production plants, and its Changping filing and packaging facility.
Eddingpharm a specialty pharmaceutical company based in China, has announced that the company has entered into a collaboration agreement with GSK, whereby Eddingpharm will acquire from GSK the exclusive right in mainland China to import, market, promote, distribute and sell Tykerb, a treatment for advanced or metastatic breast cancer that was recently approved by the SFDA.
Chinese state media say a court has sentenced seven people to prison for producing chromium-tainted gel medicine capsules. The scandal that was exposed in April 2012 was the latest to rock China's pharmaceutical industry, which suffers from abundant fakery and substandard ingredients.
American Oriental Bioengineering, Inc., today announced that four out of its five manufacturing subsidiaries are undergoing onsite short notice inspections directed by China State Food and Drug Administration ("SFDA").
BEIJING (AP) — China's State Food and Drug Administration has suspended the sale of 13 drugs that it says are believed to have been made with capsules that contain excessive chromium.
Novartis said today that it received Chinese regulatory approval for its eye drug Lucentis, and it is launching the diabetes treatment Galvus in China.
WuXi PharmaTech, a pharmaceutical, biotechnology and medical device research and development outsourcing company with operations in China and the United States, today announced that it had been awarded a Certificate of Good Laboratory Practice (GLP) compliance from the State Food and Drug Administration (SFDA), China's regulatory authority for pharmaceuticals, for its toxicology facility in Suzhou.
Simcere Dongyuan Pharmaceutical Co., Ltd. has recently received SFDA new drug certification and registration approval to manufacture and market Palonosetron material and injections in China.
NeoStem's Suzhou Erye Pharmaceutical Subsidiary Passes Government Inspection for Two Manufacturing Lines at its New FacilityJune 15, 2010 4:42 am | News | Comments
NeoStem, Inc., an international biopharmaceutical company with operations in the U.S. and China, announced that its Suzhou Erye pharmaceutical subsidiary ("Erye") passed the government inspection by the State Food and Drug Administration ("SFDA") in China to manufacture penicillin powder for injection and cephalosporin powder for injection at its new manufacturing facility which provides 50% greater manufacturing capacity than its existing plant.
BEIJING (AP) — The deputy head of China's food and drug regulator is being investigated and has been dismissed from his post, a state news agency said Sunday, citing an anti-corruption agency.
Sinovac Biotech Ltd., a China-based vaccine manufacturer, announced today that it has received the confirmation from the China International Tendering Company that Sinovac was selected by the Beijing Centers for Diseases Control and Prevention (Beijing CDC) to supply the Company's hepatitis A vaccine, Healive, to the Beijing Expanded Program of Immunization (EPI).
Sinovac Biotech Ltd., a China-based vaccine manufacturer, announced today that its 30%-owned joint venture, Sinovac Dalian, has submitted an application to China's State Food and Drug Administration (SFDA) to commence human clinical trials for its mumps vaccine.
MicuRx Pharmaceuticals, Inc., a privately-held biopharmaceutical company developing next-generation antibiotics, today announced that it has filed an Investigational New Drug (IND) application with the State Food and Drug Administration (SFDA) in China for MRX-I
Lotus Pharmaceuticals, Inc., a growing developer and producer of prescription drugs and licensed national seller of pharmaceutical products in the People's Republic of China ("PRC"), reported the groundbreaking ceremony on March 9 to construct a new building complex on the grounds of its production facility in Beijing.
Simcere Pharmaceutical Group, a pharmaceutical company specializing in the development, manufacturing, and marketing of branded generic and proprietary pharmaceuticals in China,